Rhythm Pharmaceuticals (RYTM) Expected to Announce Quarterly Earnings on Wednesday

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 7th. Analysts expect Rhythm Pharmaceuticals to post earnings of ($0.67) per share and revenue of $40.43 million for the quarter.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The firm had revenue of $41.83 million during the quarter, compared to the consensus estimate of $38.48 million. On average, analysts expect Rhythm Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Rhythm Pharmaceuticals Trading Up 0.3 %

Shares of NASDAQ:RYTM traded up $0.21 during trading on Friday, reaching $64.01. The stock had a trading volume of 475,184 shares, compared to its average volume of 549,602. The firm's 50-day simple moving average is $56.09 and its 200 day simple moving average is $56.61. Rhythm Pharmaceuticals has a one year low of $35.17 and a one year high of $68.58. The company has a market capitalization of $4.05 billion, a P/E ratio of -14.78 and a beta of 2.32.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on RYTM shares. Morgan Stanley reaffirmed an "overweight" rating and issued a $72.00 price target on shares of Rhythm Pharmaceuticals in a report on Friday, March 7th. Wells Fargo & Company increased their price target on Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the company an "overweight" rating in a research note on Monday, April 7th. Bank of America upgraded Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 price target on the stock in a research note on Monday, April 7th. Jefferies Financial Group began coverage on shares of Rhythm Pharmaceuticals in a research note on Thursday, January 2nd. They issued a "buy" rating and a $80.00 target price for the company. Finally, Stifel Nicolaus began coverage on shares of Rhythm Pharmaceuticals in a research note on Wednesday, March 5th. They set a "buy" rating and a $78.00 price target on the stock. Thirteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $74.92.

Insider Activity

In other Rhythm Pharmaceuticals news, EVP Yann Mazabraud sold 6,745 shares of the stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $65.08, for a total transaction of $438,964.60. Following the transaction, the executive vice president now owns 37,655 shares in the company, valued at approximately $2,450,587.40. This represents a 15.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Pamela J. Cramer sold 7,031 shares of the business's stock in a transaction that occurred on Tuesday, April 29th. The shares were sold at an average price of $65.09, for a total value of $457,647.79. Following the completion of the sale, the insider now owns 19,209 shares of the company's stock, valued at $1,250,313.81. This trade represents a 26.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 160,417 shares of company stock worth $9,008,789 in the last ninety days. Company insiders own 5.60% of the company's stock.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.